Clinical TrialsTaysha is well on its way to dosing its first patient in the pivotal Part B of the REVEAL study in Rett patients.
Regulatory MilestonesTaysha has taken all the right steps to reduce regulatory risk, as evidenced by their BTD designation.
Strategic DirectionTSHA has regained full rights to TSHA-102, indicating strong control over its strategic direction.